Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.

Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Spartà A, McCubrey JA, Martelli AM.

Expert Opin Ther Targets. 2013 Aug;17(8):921-36. doi: 10.1517/14728222.2013.808333. Epub 2013 Jun 11. Review.

PMID:
23755894
2.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.

Oncotarget. 2010 Jun;1(2):89-103. Review.

3.

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L.

Curr Med Chem. 2007;14(19):2009-23. Review.

PMID:
17691943
4.

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.

Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.

Expert Opin Investig Drugs. 2009 Sep;18(9):1333-49. doi: 10.1517/14728220903136775. Review.

PMID:
19678801
5.

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.

Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, Manzoli L, Cappellini A, McCubrey JA.

Expert Opin Ther Targets. 2012 Jul;16(7):729-42. doi: 10.1517/14728222.2012.694869. Epub 2012 Jun 12. Review.

PMID:
22686561
6.

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.

Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102. Epub 2010 Sep 30.

7.

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.

Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM.

Leukemia. 2008 Jan;22(1):147-60. Epub 2007 Oct 11.

PMID:
17928881
8.

Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.

Del Poeta G, Bruno A, Del Principe MI, Venditti A, Maurillo L, Buccisano F, Stasi R, Neri B, Luciano F, Siniscalchi A, de Fabritiis P, Amadori S.

Curr Cancer Drug Targets. 2008 May;8(3):207-22. Review.

PMID:
18473734
9.

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.

Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM.

Cancer Res. 2008 Nov 15;68(22):9394-403. doi: 10.1158/0008-5472.CAN-08-2815.

10.

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.

Hassan HT, Zander A.

Acta Haematol. 1996;95(3-4):257-62. Review.

PMID:
8677752
11.

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.

Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, McCubrey JA.

Leukemia. 2010 Apr;24(4):687-98. doi: 10.1038/leu.2010.32. Epub 2010 Mar 4.

PMID:
20200557
12.

PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.

Ding Q, Gu R, Liang J, Zhang X, Chen Y.

Med Oncol. 2013 Mar;30(1):395. doi: 10.1007/s12032-012-0395-5. Epub 2013 Jan 19.

PMID:
23335068
13.

Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.

Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N Jr, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M.

Cancer Res. 2006 Apr 1;66(7):3737-46.

14.

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Haematologica. 2010 Mar;95(3):415-23. doi: 10.3324/haematol.2009.010785. Epub 2009 Dec 8.

15.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S.

Blood. 2013 Oct 3;122(14):2443-52. doi: 10.1182/blood-2013-03-491431. Epub 2013 Aug 27.

16.
17.

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias.

Chiarini F, Evangelisti C, Buontempo F, Bressanin D, Fini M, Cocco L, Cappellini A, McCubrey JA, Martelli AM.

Curr Cancer Drug Targets. 2012 Nov 21. [Epub ahead of print]

PMID:
23215723
18.

Current and emerging therapies for acute myeloid leukemia.

Robak T, Wierzbowska A.

Clin Ther. 2009;31 Pt 2:2349-70. doi: 10.1016/j.clinthera.2009.11.017. Review.

PMID:
20110045
19.

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.

Leukemia. 2006 Jun;20(6):911-28. Review.

PMID:
16642045
20.

Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.

Brown P, Smith FO.

Paediatr Drugs. 2008;10(2):85-92. Review.

PMID:
18345718
Items per page

Supplemental Content

Write to the Help Desk